Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Cabre

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
JAMA Neurology|July 1, 2024
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple SclerosisAntoine Gavoille, Fabien Rollot, Romain Casey, et al.
JAMA Neurology|March 25, 2024
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MSGuillaume Jouvenot, Guilhem Courbon, Mathilde Lefort, et al.
Journal of Neurology|April 2, 2024
The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sexNaila Makhani, Christine Lebrun-Frenay, Aksel Siva, et al.
JAMA Neurology|May 27, 2015
Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum DisorderStephane Kremer, Felix Renard, Sophie Achard, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 4, 2015
Update on biomarkers in neuromyelitis opticaEsther Melamed, Michael Levy, Patrick J Waters, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2021
Determinants of therapeutic lag in multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
CNS Drugs|April 4, 2026
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort StudyIzanne Roos, Sifat Sharmin, Serkan Ozakbas, et al.
Neurology|August 17, 2022
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple SclerosisIzanne Roos, Charles Malpas, Emmanuelle Leray, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Multiple Sclerosis and Related Disorders|June 11, 2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studiesJohanna B Andersen, Sifat Sharmin, Mathilde Lefort, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
JAMA Neurology|July 1, 2024
Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple SclerosisAntoine Gavoille, Fabien Rollot, Romain Casey, et al.
JAMA Neurology|March 25, 2024
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MSGuillaume Jouvenot, Guilhem Courbon, Mathilde Lefort, et al.
Journal of Neurology|April 2, 2024
The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sexNaila Makhani, Christine Lebrun-Frenay, Aksel Siva, et al.
JAMA Neurology|May 27, 2015
Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum DisorderStephane Kremer, Felix Renard, Sophie Achard, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 4, 2015
Update on biomarkers in neuromyelitis opticaEsther Melamed, Michael Levy, Patrick J Waters, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 11, 2021
Determinants of therapeutic lag in multiple sclerosisIzanne Roos, Emmanuelle Leray, Federico Frascoli, et al.
CNS Drugs|April 4, 2026
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort StudyIzanne Roos, Sifat Sharmin, Serkan Ozakbas, et al.
Neurology|August 17, 2022
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple SclerosisIzanne Roos, Charles Malpas, Emmanuelle Leray, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Multiple Sclerosis and Related Disorders|June 11, 2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studiesJohanna B Andersen, Sifat Sharmin, Mathilde Lefort, et al.
Pageof 8